OLMA
Income statement / Annual
Last year (2023), Olema Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Olema Pharmaceuticals, Inc.'s net income was -$96.66 M.
See Olema Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$377,000.00
|
$1.66 M
|
$1.66 M
|
$11,000.00
|
$9,033.00
|
$8,244.00
|
| Gross Profit |
-$377,000.00
|
-$1.66 M
|
-$1.66 M
|
-$11,000.00
|
-$9,033.00
|
-$8,244.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$86.14 M
|
$82.27 M
|
$51.10 M
|
$13.70 M
|
$3.92 M
|
$1.69 M
|
| General & Administrative Expenses |
$18.82 M
|
$24.71 M
|
$20.39 M
|
$7.82 M
|
$403,000.00
|
$386,000.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$18.82 M
|
$24.71 M
|
$20.39 M
|
$7.82 M
|
$403,000.00
|
$386,000.00
|
| Other Expenses |
$0.00
|
-$27,000.00
|
-$47,000.00
|
$0.00
|
$0.00
|
-$31,000.00
|
| Operating Expenses |
$104.96 M
|
$106.99 M
|
$71.49 M
|
$21.53 M
|
$4.32 M
|
$2.08 M
|
| Cost And Expenses |
$104.96 M
|
$106.99 M
|
$71.49 M
|
$21.53 M
|
$4.32 M
|
$2.08 M
|
| Interest Income |
$8.32 M
|
$2.23 M
|
$442,000.00
|
$60,000.00
|
$7,000.00
|
$4,000.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$653,000.00
|
$0.00
|
$28,000.00
|
| Depreciation & Amortization |
$377,000.00
|
$1.66 M
|
$1.66 M
|
$11,000.00
|
$9,033.00
|
$8,244.00
|
| EBITDA |
-$104.58 M |
-$103.13 M |
-$69.43 M |
-$21.52 M |
-$4.31 M |
-$2.16 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$8.31 M
|
$2.20 M
|
$395,000.00
|
-$593,000.00
|
$7,000.00
|
-$118,000.00
|
| Income Before Tax |
-$96.66 M
|
-$104.79 M
|
-$71.10 M
|
-$22.12 M
|
-$4.32 M
|
-$2.20 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$2.20 M
|
-$210,000.00
|
$642,000.00
|
-$155,860.00
|
-$90,000.00
|
| Net Income |
-$96.66 M
|
-$102.59 M
|
-$70.89 M
|
-$22.76 M
|
-$4.32 M
|
-$2.20 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.14 |
-2.56 |
-1.79 |
-0.58 |
-0.11 |
-0.16 |
| EPS Diluted |
-2.14 |
-2.56 |
-1.79 |
-0.58 |
-0.11 |
-0.16 |
| Weighted Average Shares Out |
$45.25 M
|
$40.00 M
|
$39.52 M
|
$39.31 M
|
$40.17 M
|
$14.10 M
|
| Weighted Average Shares Out Diluted |
$45.25 M
|
$40.00 M
|
$39.52 M
|
$39.31 M
|
$40.17 M
|
$14.10 M
|
| Link |
|
|
|
|
|
|
